Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Neuer Top-Geologe an Bord - zündet jetzt die nächste Kursrakete?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40J1L | ISIN: CA22112H1010 | Ticker-Symbol: ET8
Tradegate
04.06.25 | 19:20
3,240 Euro
-1,82 % -0,060
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
COSCIENS BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
COSCIENS BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,2403,34004.06.

Aktuelle News zur COSCIENS BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrCOSCIENS Biopharma reconstitutes board1
FrCOSCIENS Biopharma Inc. - 6-K, Report of foreign issuer2
FrCOSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders200Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement...
► Artikel lesen
26.05.Cosciens Biopharma Inc: Cosciens Biopharma dissident nominates six directors4
COSCIENS BIOPHARMA Aktie jetzt für 0€ handeln
26.05.COSCIENS Biopharma To Review Director Nominations From Goodwood2
26.05.COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders1
23.05.Cosciens Biopharma Inc: Cosciens dissident Goodwood to nominate six directors7
23.05.Goodwood to Nominate New Directors for COSCIENS Biopharma Inc.1
20.05.COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer4
13.05.COSCIENS Biopharma GAAP EPS of -$1.16, revenue of $1.5M4
13.05.COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update122Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures...
► Artikel lesen
13.05.COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer1
02.05.COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer3
14.04.Cosciens Biopharma Inc: Cosciens Biopharma appoints Biehn as CEO4
14.04.COSCIENS Biopharma ernennt Anna Biehn zur neuen CEO4
14.04.COSCIENS Biopharma names Anna Biehn as new CEO1
14.04.COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer18925+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels Current President and CEO...
► Artikel lesen
09.04.COSCIENS Biopharma Inc. - 20-F, Annual and transition report of foreign private issuers3
09.04.COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer2
09.04.COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update178Fully repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Ongoing streamlined efficiencies and cost cutting measures taken to refine operations...
► Artikel lesen
Seite:  Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,15